Abstract: The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.

Abstract: The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.

Abstract: The invention relates to bicyclic heterocycle compounds of formula (I): or tautomeric or stereochemically isomeric forms, N-oxides, pharmaceutically acceptable salts or the solvates thereof; wherein R1, R2, R3, A, W, U and V are as defined herein; to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

Abstract: The invention provides compounds of the formula (I): The compounds have activity against cyclin dependent kinases, glycogen synthase kinase and Aurora kinases and are therefore useful to treat cancer and viral diseases.

Abstract: The invention provides compounds of the formula (I): and salts, tautomers, solvates and N-oxides thereof; wherein Q is CH or N; X is N, N+—O? or CR3; Y is N, N+—O? or CR3a; R1 and R2 are independently selected from hydrogen and various substituents as defined in the claims; or R1 and R2 together with the atoms to which they are attached, link to form an optionally substituted carbocyclic or heterocyclic aromatic or non-aromatic ring of 4 to 7 members; R3 is selected from hydrogen and various substituents; and R3a is selected from hydrogen and various substituents as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds. The compounds of formula (I) have activity as inhibitors of CDK kinases and are useful in the treatment of inter alia proliferative diseases such as cancers.

Abstract: Systems and methods for mounting optics to an LED lighting module include a retainer engageable with the lighting module and a removable upper plate for securing the optics in the retainer.

Abstract: A method of operating a drive system for a load is disclosed. The drive system may have an electric motor/generator and a gas turbine engine. The engine may have a combustor, and main and pilot flow paths via which fuel is supplied to the combustor. The engine may be operable in low and standard emissions modes. A proportion of the fuel that is supplied to the combustor via the pilot flow path may be greater in the standard emissions mode than in the low emissions mode. The method may include determining an engine power requirement of the load, and whether the engine power requirement of the load is sufficiently large to operate the engine in the low emissions mode. Additionally, the method may include operating the electric motor/generator if the engine power requirement of the load is not sufficiently large to operate the engine in the low emissions mode.

Abstract: A method of operating a drive system for a load is disclosed. The drive system may have an electric motor/generator and a gas turbine engine. The engine may have a combustor, and main and pilot flow paths via which fuel is supplied to the combustor. The engine may be operable in low and standard emissions modes. A proportion of the fuel that is supplied to the combustor via the pilot flow path may be greater in the standard emissions mode than in the low emissions mode. The method may include determining an engine power requirement of the load, and whether the engine power requirement of the load is sufficiently large to operate the engine in the low emissions mode. Additionally, the method may include operating the electric motor/generator if the engine power requirement of the load is not sufficiently large to operate the engine in the low emissions mode.

Abstract: Invention for efficiently transmitting energy to a target for producing an overall effective result for applications comprising power transmission and communications. Wherein, first, a source of electromagnetically intense coherent radiation and interferometric apparatus produce a beam of electromagnetically neutralized radiation. The neutralized beam comprises forward propagating photons or forward propagating electrically charged particles which comprise associated forward traveling transverse waves which superimpose and destructively interfere to an extent, and comprise associated oscillatorily time-varying electromagnetic fields which cancel to a corresponding extent. Then, second, the electromagnetically neutralized beam is coherently transmitted through transmission apparatus to a target.

Abstract: Invention for pattern recognition and artificial intelligence comprising: 1) storing data in parallel by applying a logic level (1) input or a logic level (0) input to one input of each of at least two exclusive-nor logic gates; 2) comparing data in parallel by applying a logic level (1) input or a logic level (0) input to the other input of each of the exclusive-nor gates, wherein each exclusive-nor gate produces a logic level (1) output when both inputs have the same datum input, and each exclusive-nor gate produces a logic level (0) output when both inputs have different datum input; and 3) measuring the outputs of the exclusive-nor logic circuits collectively with a measuring apparatus, wherein the percentage of the pattern input for comparison which matches the pattern of data stored in the exclusive-nor gates is directly proportional to the magnitude of the collective output of the exclusive-nor gates.

Abstract: Integrated solar modules are provided. In one example, a corner cap for coupling to a solar module is described. The solar module has a solar panel and a frame circumscribing the solar panel. The corner cap includes a first wall and a second wall. The first wall and the second wall define a corner angle substantially the same as an angle defined by a corner of the solar module. The corner cap includes a flange extending from the corner cap. The flange is configured for coupling the corner cap to a solar module.

Abstract: An isolated epitaxial modulation device comprises a substrate; a barrier structure formed on the substrate; an isolated epitaxial region formed above the substrate and electrically isolated from the substrate by the barrier structure; a semiconductor device, the semiconductor device located in the isolated epitaxial region; and a modulation network formed on the substrate and electrically coupled to the semiconductor device. The device also comprises a bond pad and a ground pad. The isolated epitaxial region is electrically coupled to at least one of the bond pad and the ground pad. The semiconductor device and the epitaxial modulation network are configured to modulate an input voltage.

Abstract: A soluble compound for preventing or reducing blood coagulation comprising an antithrombotic agent and a membrane binding element, wherein the antithrombotic agent has a weight of less than about 5,000 daltons. Also disclosed is a soluble compound for preventing or reducing blood coagulation comprising an anticoagulant joined to a membrane binding element via a joining element, wherein the joining element between the anticoagulant and the membrane binding element is less than about 10,000 daltons in weight. These compounds can be used in therapy and, in particular, in preventing or reducing blood coagulation. As a result, a method of treatment is provided comprising administering an effective amount of the compounds to a subject to prevent or reduce blood coagulation as well as a method of perfusing an organ, tissue or cell comprising contacting the compounds with the organ, tissue or cell to prevent or reduce blood coagulation.

Abstract: A computer implemented method, system, and computer program product include one or more processors providing a framework for building a visual representation of a product concept, the visual representation including one or more of a textual component and a graphical component; one or more processors receiving a designation of an element within at least one of the textual component and the graphical components as a dynamic element; one or more processors associating the dynamic element with a variant list including one or more element variants; one or more processors receiving a selection of a first element variant from the variant list; and one or more processors generating a first instantiation of the visual representation including the first element variant as the dynamic element.

Abstract: A computer implemented method, system, and computer program product include one or more processors providing a framework for building a visual representation of a product concept, the visual representation including one or more of a textual component and a graphical component; one or more processors receiving a designation of an element within at least one of the textual component and the graphical components as a dynamic element; one or more processors associating the dynamic element with a variant list including a plurality of element variants; one or more processors receiving a selection of a subset of the plurality of element variants from the variant list; and one or more processors generating a first instantiation of the visual representation including a combination of the subset of the plurality of element variants as the dynamic element.

Abstract: A computer implemented method, system, and computer program product include one or more processors identifying a dynamic element within framework for building a visual representation of a product concept, the visual representation including one or more of a textual component and a graphical component, the dynamic element associated with a variant list including one or more variant elements; one or more processors identifying one of a longest variant element and a shortest variant element from within the variant list; and one or more processors generating a first instantiation of a visual representation of a product concept including the one of the longest variant element and the shortest variant element as the dynamic element.

Abstract: A framework is provided for building a visual representation of a product concept including a textual component and/or a graphical component. A first element within one of the textual component and the graphical components is designated as a first dynamic element. A second element within one of the textual component and the graphical component is designated as a second dynamic element. The first dynamic element is associated with a first variant list. The second dynamic element is associated with a second variant list. A constraint is associated between at least a first element variant and at least a second element variant. A selection of a first element variant from the first variant list and a second element variant from the second variant list are received. A first instantiation of the visual representation is generated including the first element variant and the second element variant based upon the constraint.

Abstract: A framework is provided for building a visual representation of a product concept including a textual component and/or a graphical component. A designation is received of a first element within at least one of the textual component and the graphical components as a dynamic element. The dynamic element is associated with a variant list including one or more element variants. A second element corresponding to the first element is identified. The second element is linked with the first element. A selection of a first element variant from the variant list is received. A first instantiation of the visual representation is generated including the first element variant as the dynamic element and including the first element variant as the second element.

Abstract: The invention provides a compound of the formula (I): or a salt, solvate, tautomer or N-oxide thereof, wherein M is selected from a group D1 and a group D2: and R?, E, A and X are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds, processes for making the compounds and the use of the compounds in the prophylaxis or treatment of a disease state mediated by a CDK kinase, GSK-3 kinase or Aurora kinase.